134 related articles for article (PubMed ID: 33422766)
1. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
[TBL] [Abstract][Full Text] [Related]
2. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Lee SM; Falzon M; Blackhall F; Spicer J; Nicolson M; Chaudhuri A; Middleton G; Ahmed S; Hicks J; Crosse B; Napier M; Singer JM; Ferry D; Lewanski C; Forster M; Rolls SA; Capitanio A; Rudd R; Iles N; Ngai Y; Gandy M; Lillywhite R; Hackshaw A
J Clin Oncol; 2017 Feb; 35(4):402-411. PubMed ID: 27893326
[TBL] [Abstract][Full Text] [Related]
3. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
4. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
5. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.
Huang SJ; Wang YF; Jin ZY; Sun JY; Guo ZL
Tumour Biol; 2014 May; 35(5):4023-9. PubMed ID: 24370899
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
Takemoto S; Nakamura Y; Gyoutoku H; Senju H; Ogawara D; Ikeda T; Yamaguchi H; Kitazaki T; Nakano H; Nakatomi K; Tomari S; Sato S; Nagashima S; Fukuda M; Mukae H
Thorac Cancer; 2019 Mar; 10(3):452-458. PubMed ID: 30628188
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.
Yamashita F; Azuma K; Yoshida T; Yamada K; Kawahara A; Hattori S; Takeoka H; Zaizen Y; Kawayama T; Kage M; Hoshino T
PLoS One; 2013; 8(8):e71356. PubMed ID: 23940741
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das M; Riess JW; Frankel P; Schwartz E; Bennis R; Hsieh HB; Liu X; Ly JC; Zhou L; Nieva JJ; Wakelee HA; Bruce RH
Lung Cancer; 2012 Aug; 77(2):421-6. PubMed ID: 22555222
[TBL] [Abstract][Full Text] [Related]
15. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
[TBL] [Abstract][Full Text] [Related]
16. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
17. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q
Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Azuma K; Komohara Y; Sasada T; Terazaki Y; Ikeda J; Hoshino T; Itoh K; Yamada A; Aizawa H
Cancer Sci; 2007 Sep; 98(9):1336-43. PubMed ID: 17640298
[TBL] [Abstract][Full Text] [Related]
19. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]